TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16924010

Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg) treatment
Number of subjects: 33
Study: 15675752

Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Empirical therapy using benzylpenicillin in control group
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Empirical therapy using benzylpenicillin in prophylaxis group
Number of subjects: 1226
Study: 16403928

Group type: COMPARATOR
Intervention: Beta-blocker alone
Number of subjects: 412

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 412

Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker
Number of subjects: 412

Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker vs beta-blocker alone
Number of subjects: 412

Group type: COMPARATOR
Intervention: Sotalol vs beta-blocker alone
Number of subjects: 412

Group type: COMPARATOR
Intervention: Amiodarone plus beta-blocker vs sotalol
Number of subjects: 412
Study: 10319306

Group type: EXPERIMENTAL
Intervention: Metrogel Vaginal (one applicator twice daily for five days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole (500 mg twice daily for seven days by mouth)
Number of subjects: 60
Study: 7577275

Group type: EXPERIMENTAL
Intervention: Crystalloid preloading (1 litre lactated Ringer's)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Colloid preloading (0.5 litre hydroxyethyl starch)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both crystalloid and colloid preloading
Number of subjects: 26
Study: 2023164

Group type: EXPERIMENTAL
Intervention: Temazepam 20mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temazepam 10mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6784566

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (2%, 15 mg) administered every 6 hours for 48 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo ointment administered every 6 hours for 48 hours
Number of subjects: 10
Study: 30673620

Group type: EXPERIMENTAL
Intervention: High-accruing institutions (HAIs) (≥10 enrolled patients)
Number of subjects: 1252

Group type: COMPARATOR
Intervention: Low-accruing institutions (LAIs) (≤ 9 enrolled patients)
Number of subjects: 1252
Study: 29064909

Group type: EXPERIMENTAL
Intervention: Pexacerfont (300, 200, and 100 mg/day in the first, second, and third week, respectively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pexacerfont
Number of subjects: 0
Study: 26847973

Group type: EXPERIMENTAL
Intervention: Sleep problems at baseline
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Emotional problems at baseline
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Sleep problems and emotional problems from 6-12 months
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Sleep problems and conduct problems
Number of subjects: 270
Study: 24468078

Group type: EXPERIMENTAL
Intervention: Aqueous gel
Number of subjects: 95

Group type: COMPARATOR
Intervention: Talcum powder
Number of subjects: 95
Study: 22540391

Group type: EXPERIMENTAL
Intervention: Aerobic endurance training, moderate intensity, supervised by a sport therapist, at least 3 times a week for 12 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Relaxation training, Jacobson's progressive muscle relaxation, guided by a trained relaxation therapist, at least 3 times a week for 12 weeks.
Number of subjects: 60
Study: 19939467

Group type: EXPERIMENTAL
Intervention: Dried blood spots (DBS) from Guthrie cards
Number of subjects: 84

Group type: COMPARATOR
Intervention: Blood samples from blood collecting tubes
Number of subjects: 84
Study: 17414902

Group type: EXPERIMENTAL
Intervention: Prevention program for low back pain (LBP) in an occupational setting
Number of subjects: 489

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 489
Study: 16336673

Group type: EXPERIMENTAL
Intervention: Inhaled dry powder mannitol (M)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Hypertonic (4.5%) saline (HS)
Number of subjects: 592
Study: 12020908

Group type: EXPERIMENTAL
Intervention: Bipolar scissors tonsillectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall reactionary hemorrhage rate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall secondary hemorrhage rate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hospital readmission rate
Number of subjects: 50
Study: 9633846

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2, 24‐hour infusion) plus cisplatin (75 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2, 3‐hour infusion) plus carboplatin dosed to an area under curve of 7.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents (topotecan, gemcitabine, oral etoposide, encapsulated doxorubicin)
Number of subjects: 0
Study: 7886709

Group type: EXPERIMENTAL
Intervention: Recent infection within 1 week before ictus or examination
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Febrile and subfebrile infections (> or = 37.5 degrees C)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Infection as a risk factor for cerebrovascular ischemia
Number of subjects: 197
Study: 1978640

Group type: EXPERIMENTAL
Intervention: Metyrosine + Phenoxybenzamine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Phenoxybenzamine alone
Number of subjects: 25
Study: 31784280

Group type: EXPERIMENTAL
Intervention: Upper tertile pMFAP4
Number of subjects: 504

Group type: COMPARATOR
Intervention: pMFAP4 levels
Number of subjects: 504
Study: 30226087

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29938621

Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids (2500 mg) plus nano‐curcumin (80 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ω‐3 (2500 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (ω‐3 and nano‐curcumin placebo included oral paraffin oil)
Number of subjects: 80
Study: 27809886

Group type: EXPERIMENTAL
Intervention: Small Step Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25157115

Group type: EXPERIMENTAL
Intervention: ADHF patients (n = 468)
Number of subjects: 683
Study: 22733286

Group type: EXPERIMENTAL
Intervention: Group A - identical spherical nomogram adjustments
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Group B - individual adjustments of treatment sphere and treatment cylinder
Number of subjects: 146

Group type: COMPARATOR
Intervention: Reference group - internal standard nomograms without modifications
Number of subjects: 146
Study: 19557060

Group type: EXPERIMENTAL
Intervention: Boosting Better Breaks (BBB) break-time policy
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 364
Study: 17502778

Group type: EXPERIMENTAL
Intervention: 11 exclusion criteria applied to the sample of depressed adults
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: 5 most common exclusion criteria
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Standard severity cutoff score and 4 criteria relevant to safety or diagnostic validity
Number of subjects: 348
Study: 15697057

Group type: EXPERIMENTAL
Intervention: Rumination induction
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Distraction induction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no induction)
Number of subjects: 72
Study: 12095666

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Methadone (standard prison treatment)
Number of subjects: 74
Study: 9640728

Group type: EXPERIMENTAL
Intervention: Videoconferencing mode of the CAMCOG test
Number of subjects: 11

Group type: COMPARATOR
Intervention: Face-to-face mode of the CAMCOG test
Number of subjects: 11
Study: 8123862

Group type: EXPERIMENTAL
Intervention: Bu/Cy2 regimen with monoclonal antibody-purged bone marrow
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cy/fTBI regimen with monoclonal antibody-purged bone marrow
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cy/fTBI regimen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bu/Cy2 regimen
Number of subjects: 63
Study: 2775611

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (50 mg) dissolved in homogenized meal (C)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium diclofenac (50 mg) dissolved in phosphate buffer pH 7.5 (B)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium diclofenac (50 mg) dissolved in water (A)
Number of subjects: 6
Study: 198055

Group type: EXPERIMENTAL
Intervention: 99Tcm-methylene-diphosphonate (MDP)
Number of subjects: 350

Group type: COMPARATOR
Intervention: 99Tcm-pyrophosphate (PYP)
Number of subjects: 350
Study: 31589558

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 30
Study: 27639439

Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) injections
Number of subjects: 62

Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 62
Study: 25889091

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 2

Group type: COMPARATOR
Intervention: Glucose-lowering oral agents
Number of subjects: 2
Study: 23462724

Group type: EXPERIMENTAL
Intervention: AGI004 4 mg then 8 mg per 24 h transdermal patch
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AGI004 8 mg per 24 h transdermal patch
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: AGI004 4 mg per 24 h transdermal patch
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21297494

Group type: EXPERIMENTAL
Intervention: POM3 (omega-3-acid ethyl esters, 4 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 31
Study: 18304964

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CT) with cyclophosphamide (1500 mg/m2), thiotepa (150 mg/m2), and mitoxantrone (10 mg/m2) for four consecutive days followed by stem cell transplantation
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy (SD-CT) with three cycles of CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, 5-fluorouracil 600 mg/m2)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Comparison of HD-CT versus SD-CT
Number of subjects: 307
Study: 15705206

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (budesonide 400 mug)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Asthmatic patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 19
Study: 12074350

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.0 mg/day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg/day)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Overall hypertensive patients (no specific intervention mentioned)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Nontreatment hypertensive patients (no specific intervention mentioned)
Number of subjects: 235
Study: 10204880

Group type: EXPERIMENTAL
Intervention: Phase reordering with a 10 mm acceptance window
Number of subjects: 0

Group type: COMPARATOR
Intervention: Navigator acceptance window methods (acceptance‐rejection algorithm and diminishing variance algorithm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective respiratory gating technique
Number of subjects: 0
Study: 7486038

Group type: EXPERIMENTAL
Intervention: edrophonium (1 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: neostigmine (70 micrograms/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo saline
Number of subjects: 30
Study: 2208185

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 548840

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adrenalin (epinephrine eyedrops twice a day)
Number of subjects: 10
Study: 29351594

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide‐tetanus toxoid conjugate vaccine (Vi‐TT)
Number of subjects: 387
Study: 27287823

Group type: EXPERIMENTAL
Intervention: Auditory tailored health information
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Textual tailored health information
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control condition (no health information)
Number of subjects: 146
Study: 24534097

Group type: EXPERIMENTAL
Intervention: FAI with cartilage lesions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FAI without cartilage lesions
Number of subjects: 15

Group type: COMPARATOR
Intervention: FAI
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 24346384

Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Deep Breathing (DB)
Number of subjects: 66
Study: 20446856

Group type: EXPERIMENTAL
Intervention: Tiotropium therapy
Number of subjects: 0
Study: 18983314

Group type: EXPERIMENTAL
Intervention: Immediate loading (temporary restoration placed immediately)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Early loading (temporary restoration placed 28-34 days later)
Number of subjects: 266
Study: 15538594

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12752849

Group type: EXPERIMENTAL
Intervention: Geriatric care management plus POS intervention
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Geriatric care management
Number of subjects: 451

Group type: COMPARATOR
Intervention: Telephone care management
Number of subjects: 451

Group type: COMPARATOR
Intervention: Information and referral via mail
Number of subjects: 451
Study: 11106916

Group type: EXPERIMENTAL
Intervention: DHEA replacement (50 mg/day for 6 months)
Number of subjects: 36
Study: 9322326

Group type: EXPERIMENTAL
Intervention: Differentiated, individual‐based treatment program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 54
Study: 8103763

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0
Study: 3019212

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Altizide 15 mg combined with Spironolactone 25 mg
Number of subjects: 20
Study: 29532516

Group type: EXPERIMENTAL
Intervention: levocetirizine 5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: diphenhydramine 50 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 27388752

Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study: 24559095

Group type: EXPERIMENTAL
Intervention: Absent YAP1 protein expression in tamoxifen randomized patient material
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Low YAP1 mRNA expression in luminal A subgroup
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: YAP1 downregulation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: YAP1 expression in ER+ subgroup
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: YAP1 expression in ER- subgroup
Number of subjects: 144
Study: 23157199

Group type: EXPERIMENTAL
Intervention: Pregnancy intervention
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: STI intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: HIV intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 198
Study: 20920186

Group type: EXPERIMENTAL
Intervention: Zinc + Vitamin A
Number of subjects: 300

Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vitamin A
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 18407013

Group type: EXPERIMENTAL
Intervention: Faculty-led curriculum
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Web-based curriculum
Number of subjects: 138

Group type: COMPARATOR
Intervention: Established curriculum
Number of subjects: 138
Study: 16168682

Group type: EXPERIMENTAL
Intervention: 750 mg glucosamine sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1,500 mg glucosamine sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3,000 mg glucosamine sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: glucosamine sulfate
Number of subjects: 12
Study: 12211218

Group type: EXPERIMENTAL
Intervention: Ocular instillation of carteolol (0.8 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nasal instillation of carteolol (0.8 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ocular instillation of carteolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nasal instillation of carteolol
Number of subjects: 11
Study: 10770458

Group type: EXPERIMENTAL
Intervention: Sodium valproate (20 mg/kg body weight) as adjunct to neuroleptic medication
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (neuroleptics alone)
Number of subjects: 136
Study: 8685292

Group type: EXPERIMENTAL
Intervention: Transient psychoses
Number of subjects: 326

Group type: COMPARATOR
Intervention: Partial psychoses
Number of subjects: 326

Group type: COMPARATOR
Intervention: Functional psychosis study
Number of subjects: 326
Study: 14621840

Group type: EXPERIMENTAL
Intervention: OKT3 monoclonal antibody
Number of subjects: 60

Group type: COMPARATOR
Intervention: ALG (antilymphocyte globulin) polyclonal antibody
Number of subjects: 60
Study: 3909732

Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline sulphate (0.1 mg in 1 ml cellulose gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline sulphate (5-g medicated vaginal polymer ring containing 10% terbutaline sulphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaginally administered terbutaline
Number of subjects: 0
Study: 31076982

Group type: EXPERIMENTAL
Intervention: Integrated care rotation
Number of subjects: 8

Group type: COMPARATOR
Intervention: ACT team rotation
Number of subjects: 8
Study: 30049615

Group type: EXPERIMENTAL
Intervention: Near glasses provided immediately (intervention group)
Number of subjects: 751

Group type: COMPARATOR
Intervention: No glasses provided until closeout (control group)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Intervention group vs Control group
Number of subjects: 751
Study: 26467635

Group type: EXPERIMENTAL
Intervention: Index finger strength training (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study: 23958607

Group type: EXPERIMENTAL
Intervention: Integrated body‐mind‐spirit group intervention (4 sessions, >3 hours each, once per week) + routine hospital treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine hospital treatment only
Number of subjects: 30
Study: 21862012

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19930364

Group type: EXPERIMENTAL
Intervention: Cognitive training for 24 weeks
Number of subjects: 129

Group type: COMPARATOR
Intervention: Observational period followed by cognitive training
Number of subjects: 129
Study: 16760324

Group type: EXPERIMENTAL
Intervention: GeneVac-B
Number of subjects: 173

Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 173
Study: 14977666

Group type: EXPERIMENTAL
Intervention: Serial dilation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Extraction drilling
Number of subjects: 21
Study: 11700915

Group type: EXPERIMENTAL
Intervention: Simplified lesson stressing visual input
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesson directly counteracting the vision misconception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional college-level education
Number of subjects: 0
Study: 9399388

Group type: EXPERIMENTAL
Intervention: Total gastrectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control population
Number of subjects: 26
Study: 7961198

Group type: EXPERIMENTAL
Intervention: 500 mg/L CaCO3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg/L ofloxacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2000 mg/L ciprofloxacin with 5000 mg/L CaCO3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg/L ofloxacin with 5000 mg/L CaCO3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg/L ciprofloxacin with 5000 mg/L CaCO3
Number of subjects: 0

Group type: COMPARATOR
Intervention: CaCO3
Number of subjects: 0

Group type: COMPARATOR
Intervention: ofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: ciprofloxacin
Number of subjects: 0
Study: 2975595

Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg daily
Number of subjects: 25
Study: 31553121

Group type: EXPERIMENTAL
Intervention: Patient feedback condition
Number of subjects: 33

Group type: COMPARATOR
Intervention: No patient feedback condition
Number of subjects: 33
Study: 29892042

Group type: EXPERIMENTAL
Intervention: Exosomes from fasting morning plasma samples after 3 months of CPAP therapy (n=24)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exosomes from untreated patients (n=8)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exosomes from sleep fragmentation (SF) and intermittent hypoxia (IH) exposed mice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Exosomes from CPAP treated patients
Number of subjects: 32
Study: 27553385

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Wait List (WL) Control
Number of subjects: 248